Alnylam licenses gene-silencing technology

March 20, 2008 11:27 AM E-mail| |Comments ()| Text size – +

Alnylam Pharmaceuticals Inc., a Cambridge biotechnology company, said today that it licensed certain patent rights to China-based Shanghai GenePharma Co.

Alnylam focuses on developing therapies using gene-silencing technology, which aims to shut down a disease or condition at the genetic level. Shanghai GenePharma is supplier of gene-silencing technology in China.

Financial details of the deal were not disclosed.

Alnylam shares rose 21 cents to $23.94 in morning trading on the Nasdaq Stock Market. (AP)

Email this article

Invalid email address
Invalid email address

Sending your article

Your article has been sent.

« all business news updates
Col3